Validation of a tumor-informed HLA typing assay to support drug development and clinical decision making

The TSO500 HT assay has been effectively validated to genotype HLA-A, -B, and -C from tumor samples, providing valuable tumor-informed HLA allele haplotypes with high accuracy, which can aid clinicians and drug developers in selecting HLA-directed therapies and enrolling patients in HLA-restricted clinical trials across various tumor types, including uveal melanoma.